65,437 trials
Migraine
Primary: Inflammatory Gene Expression in Chronic Migraine Patients With OnabotulinumtoxinA Injection Treatment Versus No Treatment — 44.46156; 68.74241 mRNA units — p=<0.0001
Memory
Primary: Sum of Trials (I-V) — 49.09; 47.17 score on a scale
Lung Cancer
Primary: Efficacy of Pembrolizumab Re-challenge Measured by Overall Survival — 9.4; 19.1 months — p=0.016
Dementia
Primary: Zarit Burden Interview-12 (ZBI-12) — 21.4; 22.0; 20.1; 22.3 score on a scale
Malignant Neoplasm
Primary: Overall Response, Defined as the Number of Patients Who Achieve Any Response According to Disease Type in the First 6 Courses of Treatment — 1; 0 Participants
Ulcerative Colitis
Primary: Number of Participants Who Experienced an Adverse Event (AE) — 7; 10; 18; 10 Participants
Yaws
Primary: Sensitivity of LAMP vs qpCR — 63.2 Percent
Healthy Aging
Primary: Antibody Titer — 127; 143; 241; 160 Titer
Early Detection of Cancer · Lung Neoplasms
Primary: Number of Participants With Lung Cancer Screening (LCS) Care-Gap Closed — 588 Participants
Chronic Pain
Primary: Simulated Driving Performance Task Measuring Divided Attention — 3.42; 2.57 units on a scale
Behavior
Primary: Number of Prescribing Errors by Study Arm — 8; 34; 8; 31 Medication orders
Breast Cancer · Biopsy Wound
Primary: Number of Participants by Pain Intensity at Day 4 Post Breast Biopsy With a Benefit of Intervention by E-health (Phone Consultation With a Professional or Connected…
Sudden Cardiac Death · Sudden Cardiac Arrest · Heart Failure
Primary: Percentage of Patients With LVEF Recovery at Day 90 and 180 — 222; 0; 0; 0 Participants
Cigarette Smoking-Related Carcinoma
Primary: PET/CT Imaging of the Head — 2.81; 2.40 %TAD/kg
Tobacco Smoking · Second Hand Tobacco Smoke · Smoking Cessation
Primary: Parental Combusted Tobacco Quit Rate at 12 Months — 34; 26 Participants